The human cardiac transient outward K + current I to (encoded by Kv4.3 or KCND3) plays an important role in phase 1 rapid repolarization of cardiac action potentials in the heart. However, modulation of I to by intracellular signal transduction is not fully understood. The present study was therefore designed to determine whether/how human atrial I to and hKv4.3 channels stably expressed in HEK 293 cells are regulated by protein tyrosine kinases (PTKs).
Introduction
The transient outward potassium current I to in human and canine hearts is mainly encoded by the Kv4.3 (KCND3) gene.
1, 2 Cardiac I to is regulated by various endogenous molecules and signal pathways. 3 Alpha-adrenergic stimulation inhibits cardiac I to in rabbit ventricular myocytes. 4 I to in human cardiac myocytes and cloned hKv4.3 current expressed in mammalian cells are reduced by protein kinase C (PKC). 5, 6 Activation of Ca 2+ /calmodulin-dependent protein kinase II (CaMKII) slows Kv4.3 current inactivation and accelerates the recovery rate from inactivation of the current via directly phosphorylating S550 located in C-terminus. 7 Nitric oxide inhibited Kv4.3 channels expressed in CHO cells and human atrial I to by activating adenylate cyclase and the subsequent activation of PKA and the serine/threonine phosphatase 2A. 8 Our earlier study demonstrated that genistein, a broad-spectrum inhibitor of protein tyrosine kinases (PTKs), decreased I to in rat ventricular myocytes by inhibiting PTKs; the inhibition effect was antagonized by orthovanadate, an inhibitor of protein tyrosine phosphatases (PTPs). 9 Consistent with our report, a recent study demonstrated that a functional interaction was present in between Kv4.3 channels expressed in HEK 293 cells and c-Src tyrosine kinase; furthermore, the tyrosine phosphorylation of hKv4,3 protein was mediated by SH2 and SH3 domains of c-Src kinases. 10 However, a more recent report showed that genistein inhibited Kv4.3 channels stably expressed in CHO cells via a tyrosine phosphorylation-independent mechanism. 11 This raises the question whether cardiac I to /Kv4.3 channels are regulated by PTKs. In the present study, we utilized the multiple experimental approaches including electrophysiology, immunoprecipitation, Western blotting, and mutagenesis to investigate whether/how human atrial I to and hKv4.3 channels stably expressed in HEK 293 cells are regulated by PTKs. We found that both Src-family kinases and EGFR kinase regulated human cardiac I to and hKv4.3 channels via phosphorylating tyrosine residues in the Nterminus of the channel.
Materials and Methods

Human atrial myocyte preparation
Human atrial specimens of human right atrial appendage were obtained from patients undergoing coronary artery bypass grafting. The procedure for obtaining the tissues was approved by the Ethics Committee of the University of Hong Kong (UW-10-174), with the patients' consent. The investigation conforms with the principles outlined in the Declaration of Helsinki (see Cardiovascular Research 1997;35:2-4) for use of human tissue. Human atrial myocytes were enzymatically isolated from the procedure as described previously 12, 13 and in Supplemental Methods. The isolated myocytes were kept at room temperature in the KB medium 12, 13 at least 1 h before use.
Cell culture, mutagenesis and gene transfection
The pCDNA3.1/hKv4.3 plasmid was kindly provided by Dr. Klaus Steinmeyer (Sanofi-Aventis Deutschland GmbH), and transfected into HEK 293 cells (ATCC, Manassas, VA). The HEK 293 cell line stably expressing hKv4.3 channels was established as described previously 14, 15 and in Supplemental Methods.
Solutions and chemicals
Compositions of Tyrode solution and pipette solutions are described in Supplemental Methods. [3,4-d] pyrimidin-4-amine (PP2) was purchased from Tocris Bioscience (Bristol, UK). Other reagents were obtained from Sigma-Aldrich (St Louis, MO). Stock solutions were made in dimethyl sulfoxide (DMSO) for genistein (100 mM), AG556 (100 mM), PP2 (10 mM). The stocks were aliquoted and stored at -20°C. Sodium orthovanadate stock solution (100 mM) was made in distilled water and pH value was adjusted to 9.0 with HCl.
Electrophysiology
Current recording for I to and Kv4.3 current and action potential recording were performed as described previously 12, 13 and in Supplemental Methods. Briefly, human atrial myocytes or HEK 293 cells on a cover slip were transferred to the cell chamber and superfused with Tyrode solution. After a gigaohm seal was obtained by negative pressure, the cell membrane was ruptured by applying a gentle 3 negative pressure to establish the whole-cell configuration. Series resistance (3-6 MΩ) was compensated by 80% to minimize voltage errors. Liquid junction potentials (~12 mV) between pipette and bath solutions were not corrected for the patch clamp recording. Membrane currents were measured using an EPC-10 amplifier and Pulse software (Heka Elektronik, Lambrecht, Germany). Command pulses were generated by a 12-bit digital-to-analog converter controlled by Pulse software. All current recording experiments were conducted at room temperature (22-23°C) .
Action potentials in human atrial myocytes were recorded at 36°C using a perforated patch configuration by including 200 µg/ml amphotericin B (Sigma-Aldrich) in the K + pipette solution as described previously.
1 Electrical signals were low-pass filtered at 5 kHz and stored on the hard disk of an IBM compatible computer.
Immunoprecipitation and Western blotting
The immunoprecipitation and Western blotting were performed following the procedure described previously 15, 16 and in Supplemental Methods. Briefly, HEK 293 cells (~80% confluence) stably expressing hKv4.3 channels were treated respectively with different interventions for 30 minutes at room temperature, and centrifuged at 4°C. The cell pellet was then lysed with the lysis buffer. 15, 16 Protein quantification of lysates was made using a protein assay reader (Bio-Rad Laboratories, Hercules, CA), and diluted to equal concentrations. Proteins were immunoprecipitated overnight at 4°C using 0.8 µg of anti-hKv4.3 antibody (NeuroMab, USA) and 100 µl of protein A/G beads (Upstate). Immunoprecipitated proteins bound to pelleted protein A/G beads were washed thoroughly in PBS, denatured in Laemmli sample buffer, separated using SDS-PAGE, and electroblotted onto nitrocellulose membranes. The immunoblots were probed with antiphosphotyrosine antibody (1:2000, Cell Signaling) overnight at 4°C in a blocking solution containing 5% BSA in TBS and Tween 20, and subsequently treated with goat anti-mouse IgG-HRP antibody (1:5000, Santa Cruz Biotechnology, Santa Cruz, CA) for 1 hour at room temperature. Blots were developed with enhanced chemiluminescence (ECL, GE Healthcare, Hong Kong) and exposed of Xray film (Fuji Photo Film GmbH). The blots were then stripped and reprobed with the anti-hKv4.3 channel antibody to determine total hKv4.3 channel proteins. The film was scanned, imaged by a BioImaging System (Syngene, Cambridge, UK), and analyzed via Gene Tools software (Syngene).
Statistical analysis
The data are expressed as means±SEM. Paired and/or unpaired Student's t-test were used as appropriate to evaluate the statistical significance of differences between two group means, and ANOVA was used for multiple groups. Values of P<0.05 were considered to be statistically significant. 
Effects of PTK inhibitors on I to in human atrial myocytes
Human atrial I to was recorded in the presence of 2 µM DPO-1 to limit the contamination of I Kur as described previously. 13 The effect of the broad spectrum PTK inhibitor genistein on I to was first examined in human atrial myocytes. Figure 1A shows the voltage-dependent I to recorded in a representative human atrial myocyte with voltage steps as shown in the inset before and after application of genistein (10 µM) in bath solution. The current was significantly inhibited by genistein (5 min), and the effect recovered on washout (8 min).
If genistein-induced reduction of human atrial I to is related to PTK inhibition, the effect should be antagonized by the protein tyrosine phosphatase (PTP) inhibitor orthovanadate. 15, 16 We tested the effect of orthovanadate (1 mM) on I to , but this compound had no effect on I to (n=5, data not shown). However, orthovanadate partially reversed the I to inhibition induced by 10 µM genistein in a representative myocyte (Fig. 1B) . This suggests that PTK inhibition is partially involved in I to reduction by genistein.
To determine which specific PTK is involved, the highly selective EGFR kinase inhibitor AG556 and the Src-family kinase inhibitor PP2 were tested. AG556 (10 µM) reversibly inhibited the voltage-dependent I to in a representative human atrial myocyte (Fig. 1C) . The time course of I to recorded in a typical experiment with a voltage step to +50 mV exhibits a gradual reduction of the current during 10 µM AG556 application (8 min) and the current inhibition was reversed by coapplication of AG556 with 1 mM orthovanadate (Fig. 1D ). This suggests that EGFR kinase inhibition may suppress human atrial I to . Figure 1E shows the voltage-dependent I to recorded in a representative myocyte in the absence and presence of 10 µM PP2. PP2 slightly reduced the current amplitude, and the inhibition was reversed on washout. Figure 1F displays the time course of I to recorded in a typical experiment with the voltage step shown in the inset in the absence and presence of 10 µM PP2, and with co-application of 1 mM orthovanadate. PP2 gradually decreased I to and the inhibition was partially reversed by orthovanadate. Figure 1G illustrates the percentage values of human atrial I to inhibition by genistein, AG556, or PP2 with and without co-application of orthovanadate. Genistein (10 µM) reduced I to (at +50 mV) by 13.8% (n=7, P<0.05 vs. control), and the inhibition was reversed to 7.2% by 1 mM orthovanadate (P=NS vs. genistein alone). AG556 (10 µM) inhibited I to (at +50 mV) by 35.4% (n=7, P<0.01 vs. control), and the inhibitory action was reversed by co-application of 1 mM orthovanadate to 9.3% (P<0.05 vs. AG556 alone). PP2 (10 µM) reduced the current (at +50 mV) by 12.9% (n=6, P<0.05 vs. control), and the inhibition was reversed by co-application of 1 mM orthovanadate to 7.7% (P=NS vs. PP2 alone). These results suggest that EGFR kinase and Src-family kinases likely participate in the regulation of human atrial I to .
To determine the effect of these PTK inhibitors on inactivation kinetics of human cardiac I to , the current (at +50 mV) was fitted to a mono-exponential equation in the absence and presence of genistein, AG556, or PP2 (Supplemental Fig. 1A ). Genistein (10 µM) reduced the inactivation time constant to 34.8 ± 2.3 ms from 43.4 ± 2.4 ms of control (n=6, P<0.05), AG556 (10 µM) decreased the time constant to 14.5 ± 2.5 ms from 36.1 ± 4.3 ms of control (n=6, P<0.01), while PP2 (10 µM) reduced the time constant to 29.2 ± 1.8 ms from 38.8 ± 2.3 ms of control (n=6, P<0.05), and the effect was partially reversed by orthovanadate. These results suggest that the EGFR kinase inhibition increases the inactivation of human atrial I to , and the effect of AG556 on I to inactivation was stronger than that of genistein or PP2 (P<0.05).
Alteration of action potential profile by I to reduction with PTK inhibitors
To investigate whether action potential profile would be affected with I to inhibition by the EGFR inhibitor AG556 or the Src-family inhibitor PP2, action potentials were recorded in human atrial myocytes under conditions with 2 µM DPO-1 in current clamp mode in the absence and presence of AG556 or PP2. Figure 2B shows that AG556 (10 µM) significantly prolonged early repolarization, whereas PP2 (10 µM) induced a slight prolongation of the early repolarization (Fig. 2C) in human atrial myocytes. The effect was countered by orthovanadate. The mean values (Fig. 2B ) of action potential duration at 20% and 50% repolarization (APD 20 and APD 50 ) was increased by AG556 (n=6, P<0.01 vs. control), and the effect was reversed by orthovanadate (P<0.05 or P<0.01 vs. GA556 alone). The slight alteration of APD with PP2 was not statistically significant (Fig. 2D, n=5, P=NS) . These results suggest that EGFR kinase inhibitor AG556 delays early repolarization in human atrial myocytes and the effect may be related to its significant facilitation of I to inactivation (Supplemental Figure 1 ).
Inhibition of hKv4.3 channels by PTKs inhibitors
It is well recognized that human cardiac Ito is encoded by Kv4.3 (KCND3) gene.
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To investigate potential molecular basis of PTK regulation of cardiac I to , we determined the current inhibition of genistein, AG556, and PP2, and their interaction with the PTP inhibitor orthovanadate in HEK 293 cells stably expressing hKv4.3 channels. Figure 3A shows the time course of hKv4.3 current recorded in a representative cell in the absence and presence of 10 µM genistein. Similar to the observation in I to of human atrial myocytes (Fig. 1A) , genistein reversibly inhibited hKv4.3 current amplitude. Voltage-dependent hKv4.3 current was also inhibited by genistein, and the inhibitory effect was significantly antagonized by 1 mM orthovanadate (Fig. 3B) . These results differed from the PTK-independent inhibition of genistein observed in CHO cells expressing hKv4.3 channels. 11 Our results support the notion that genistein may inhibit human atrial I to and hKv4.3 channels via both PTK-dependent and PTK-independent mechanisms. Figure 3C shows the time course of hKv4.3 current recorded in a representative cell. AG556 (10 µM) gradually inhibited hKv4.3 current and the inhibition was reversed on washout. The suppression of voltage-dependent hKv4.3 current by 10 µM AG556 was countered by 1 mM orthovanadate (Fig.  3D) . Similar to the results observed in human atrial I to , PP2 reversibly inhibited hKv4.3 current (Fig  3E) , and the inhibitory effect was antagonized by orthovanadate (Fig. 3F) . Figure 3G illustrates the percentage values of hKv4.3 current (at +50 mV) in cells treated with genistein, AG556, PP2, or co-application of orthovanadate. Genistein (10 µM) inhibited hKv4.3 current at +50 mV by 14.5% (n=6, P<0.01 vs. control), and the inhibition effect was reversed by 1mM orthovanadate to 6.7% (P<0.05 vs. genistein alone). AG556 (10 µM) inhibited the current by 48.2 % (n=6, P<0.01 vs. control), and the inhibition effect was reversed by co-application of 1 mM orthovanadate to 8.9% (P<0.01 vs. AG556 alone). PP2 (10 µM) reduced the current by 12.5% (n=6, P<0.05 vs. control), and reduction was reversed by 1 mM orthovanadate to 2.9% (P<0.05 vs. PP2 alone). These results suggest that hKv4.3 channels expressed in HEK 293 cells, like I to in human atrial myocytes, are regulated by both EGFR kinase and Src-family kinases. If this is the case, tyrosine phosphorylation level of hKv4.3 protein would be reduced by genistein, AG556, or PP2.
Similar results to those observed in human atrial I to , these three PTK inhibitors facilitated the inactivation of hKv4.3 current (Supplemental Fig. 2 ). AG556 effect on the current inactivation was stronger than that of genistein or PP2, and the effect was partially reversed by orthovanadate. It is interesting to note that hKv4.3 current reduction and the effect on current kinetics induced by AG556 were independent of the β-subunit KChIP expression (Supplement Fig. 3 ).
Tyrosine phosphorylation level of hKv4.3 channels
Tyrosine phosphorylation level of hKv4.3 protein was investigated using immunoprecipitation and Western blotting analysis in hKv4.3-HEK 293 cells, but not in human atrial myocytes, because the number of isolated human atrial myocytes is not sufficient to perform this experiment. Figure 4A shows the tyrosine phosphorylation images of hKv4.3 channels in cells treated with 20 µM genistein, 20 µM AG556, or 20 µM PP2 alone, or with the addition of 1 mM orthovanadate. 16 Genistein, AG556, or PP2 significantly reduced the phosphorylation level of hKv4.3 channel protein, and the inhibitory effects were countered by pretreatment (30 min) with 1 mM orthovanadate. Orthovanadate alone did not increase phosphorylation level of hKv4.3 protein, suggesting that the phosphorylation level of hKv4.3 channel protein is saturated under basal control conditions. was reversed by co-application of 1 mM orthovanadate to 11.1% and 4.5%, respectively (P<0.05 vs. genistein alone). AG556 inhibited the phosphorylation level by 64.3% at 20 µM (n=6, P<0.01 vs. control) and by 49.9% at 10 µM (n=4, P<0.01 vs. control), the inhibition was reversed by coapplication of 1 mM orthovanadate to 9.2% and 1.7%, respectively (P<0.01 vs. AG556 alone). PP2 reduced the phosphorylation level by 36.7% at 20 µM (n=6, P<0.01 vs. control) and by 25.6% at 10 µM (n=4, P<0.05 vs. control), and the reduction was reversed by co-application of 1 mM orthovanadate to 11.6% and 1.5%, respectively (P<0.05 vs. PP2 alone). These results indicate that the tyrosine residues of hKv4.3 channels are phosphorylated by both EGFR and Src tyrosine kinases.
Tyrosine phosphorylation sites of hKv4.3 channels
To identify the potential PTK phosphorylation sites of hKv4.3 channels, tyrosines of hKv4.3 channels with high scores of tyrosine phosphorylation were replaced by phenylalanine. Four mutants (Y108F, Y136F, Y441F and Y528F) were generated using site-directed mutagenesis technique. 27, 28 Figure 4 displays the inhibitory sensitivity of these mutants to the EGFR kinase inhibitor AG556 or the Src-family kinase inhibitor PP2. Significant current inhibition by 10 µM AG556 was observed for WT, Y108F, Y441F, and Y528F, but not for the mutant Y136F (Fig. 5A ). PP2 (10 µM) inhibited WT, Y136F, Y441F, and Y528F current, but not Y108F current (Fig. 5C) .
To further determine if Y108 and Y136 are the key tyrosine sites for phosphorylation, we constructed the double mutant Y108F-Y136F. Interestingly, this mutant lost inhibitory response to both AG556 and PP2. The percentage changes of different hKv4.3 mutants in response to AG556 and PP2 are illustrated in Fig. 5B and Fig. 5D , respectively. These results indicate that Y108 (for Srcfamily kinases) and Y136 (for EGFR kinase) are involved in the tyrosine phosphorylation of hKv4.3 channels.
It is interesting to note that the percentage values of the peak current inhibition by AG556 (Fig.  5B , 46-48%) is stronger than those by PP2 (Fig. 5D, 10-15% ). This effect is likely related to the different effects on current inactivation (AG556>PP2, Supplemental Fig 1 and Fig. 2 ) and/or different tyrosine phosphorylation inhibition (AG556>PP2, Fig. 4 ) at Y136 and Y108 of N-terminus of the channel.
If Y108 and Y136 are the dominant tyrosine residues responsible for tyrosine phosphorylation of hKv4.3 channels, replacement of tyrosine at these two sites would remarkably reduce tyrosine phosphorylation level. To test if it is the case, we performed additional experiment with immunoprecipitation and Western blot analysis. Figure 6A shows that the tyrosine phosphorylation level was dramatically reduced in HEK 293 cells expressing the double mutant Y108F-Y136F. Taken all together, these results indicate that the tyrosine phosphorylation sites of hKv4.3 channels are located at Y108 (for Src-family kinases) and Y136 (for EGFR kinase) of the N-terminus (Fig. 6B ).
Discussion
In the present study, we have demonstrated that inhibition of EGFR kinase by AG556 and Srcfamily kinases by PP2 reduce I to , and increases the current inactivation in human atrial myocytes and hKv4.3 channels stably expressed in HEK 293 cells. Tyrosine phosphorylation level of hKv4.3 channels is reduced by PTKs inhibitors genistein, AG556 and PP2. These effects are antagonized by the PTP inhibitor orthovanadate. The site-directed mutagenesis reveals that EGFR kinase is responsible for Y136 phosphorylation, whereas Src-family kinases are responsible for Y108 phosphorylation in hKv4.3 channels.
Regulation of ion channels by PTKs
PTKs, including receptor PTKs (e.g. EGFR kinase, epidermal growth factor receptor kinase) and nonreceptor PTKs (e.g. Src-family kinases), are important intracellular signals. 17 In addition to regulating cell growth, differentiation, embryonic development, metabolism, and oncogenesis. 18 PTKs modulate ion channels, including L-type Ca 2+ channels, 19 voltage-gated Na + channels, 16, 20 and volume-sensitive Cl − channels 21, 22 in mammalian heart myocytes as well as several types of K + channels in different types of cells, 9, 15, [23] [24] [25] and also TRPC channels. 26 Cardiac volume-sensitive Cl − channels, 21, 22 voltage-gated Na + channels, 16, 20 and hERG channels, 15 are regulated by both EGFR kinase and Src-family kinases, whereas cardiac slowly-delayed rectifier K + channel current (I Ks ), 10 although the broad spectrum PTKs inhibitor genistein was found to inhibit this channel via a PTK-independent pathway. 11 The present study has provided the novel information that hKv4.3 channels and I to in human atrial myocytes are regulated by both Src-family kinases and EGFR kinase.
Comparison with previous reports related to ion channels inhibition by genistein.
Genistein is a well-known broad spectrum PTKs inhibitor that may strongly inhibit the tyrosine activity of EGFR kinase and Src-family kinases and weakly inhibit PKA and PKC. 29, 30 Therefore, it has been widely used for studying ion channel regulation by PTKs. 9, 21, 23 However, PTK-independent effects of genistein were reported in native cardiac I Ks 31 and I Kr , 32 neural I Na , 33 osteoclast I Kir , 34 Kir2.1 and Kir2.3 channels expressed in Xenopus oocytes or HEK 293 cells, 35 and Kv4.3 channels expressed in CHO cells. 11 The PTK-independent results of genistein were mainly found in experiments in which the PTK-inactive analog daidzein significantly inhibited the ionic currents and/or genistein showed a remarkable inhibition in the presence of other PTK inhibitors using only an electrophysiological technique without testing whether tyrosine phosphorylation levels of these ion channels are affected by genistein. 11, [32] [33] [34] Our recent studies demonstrated the strong evidence that genistein inhibited recombinant cardiac I Ks , 24 hERG, 15 Kir2.1, 27 and Kir2.3 28 channels via a PTK-dependent mechanism. The inhibition of current amplitudes by genistein is not only accompanied with a reduction in tyrosine phosphorylation levels of these channels, but also antagonized by the PTP inhibitor orthovanadate. 15, 24, 27, 28 The present study provides additional evidence that genistein inhibits human cardiac I to and hKv4.3 channels expressed in HEK 293 cells via PTK suppression. The results obtained by us and others support the notion that genistein exhibits both PTK-dependent and PTK-independent inhibition of ion channels. Thus, it is important to note that multiple techniques are required to conclude whether a pharmacological tool shows a non-specific effect.
Novel findings of the present study
Using multiple experimental techniques including electrophysiology, immunoprecipitation, Western blot analysis, and mutagenesis, we demonstrated that human atrial I to and hKv4.3 channels were inhibited by the broad spectrum PTK inhibitor genistein, the selective EGFR kinase inhibitor AG556, and the Src-family kinase inhibitor PP2 via inhibiting PTKs, which is supported by the results in which the reduced current amplitude and tyrosine phosphorylation level are antagonized by the PTP inhibitor orthovanadate. Furthermore, the results showed that hKv4.3 channels, like hERG channels, 15 are regulated by both EGFR kinase and Src-family kinases, and the tyrosine phosphorylation is saturated under basal experimental conditions. It is unclear why this is different from a previous report in which increased hKv4.3 current amplitude and phosphorylation is observed by inhibiting PTP with bpV(phen) or application of c-Src kinase. 10 In addition, antagonistic regulation of I Cl.vol by EGFR kinase and Src-family kinases was observed in native cardiac myocytes, in which the inhibition of Src-family kinases with PP2 stimulates the current, while the inhibition of EGFR kinase with AG556 or AG1478 reduces the current. 21, 22 However, it is not the case for I to and hKv4.3 channels. Although it is unclear how hKv4.3 channels are activated by EGFR kinase and Src-family kinases, our mutagenesis results revealed that the phosphorylation sites of both EGFR kinase and Src-family kinases were located respectively at Y136 and Y108 of the N-terminus of hKv4.3 channels. The tyrosine phosphorylation level of hKv4.3 channels was dramatically reduced when these two tyrosine residues were replaced by phenylalanine.
We found that the inhibition of tyrosine phosphorylation at Y136 by the EGFR inhibitor AG556 induced a stronger facilitation of the current inactivation than that at Y108 by the Src-family kinase inhibitor PP2. This effect subsequently resulted in remarkable decrease of I to and prolongation of human atrial action potential at early repolarization (APD 20 and APD 50 ) with AG556.
Significance and limitation of the present study
I to is a voltage-gated current that is rapidly activated and inactivated in response to depolarization, 36 and plays an important role in cardiac action potential repolarization. 37 I to is heterogeneously expressed in the transmural ventricular wall from endocardium, midmyocardium, 8 and epicardium in canine and human hearts, and therefore contributes significantly to the early repolarization (phase 1) of the action potentials in these regional myocytes to maintain normal cardiac heterogeneous electrophysiology. [38] [39] [40] It is believed that I to contributes more to atrial repolarization than to ventricular repolarization in humans, 3 and reduced I to can lead to electrical remodeling in diseased human cardiomyocytes. 41, 42 Kv4.3 channel activity has been shown to be downregulated in pathological cardiac hypertrophy. [41] [42] [43] Interestingly, increasing Kv4.3 current density by in vivo overexpression of Kv4.3 gene has been found to abrogate cardiac hypertrophy. 44 In addition, cardiac Srckinase activity increases in both physiological 43 and pathological heart hypertrophy. 45 Recent studies show that EGFR plays a critical role in physiological and pathophysiological processes of the heart. 46 , 47 We therefore speculate that the level of cardiac EGFR kinase and Src-family kinase activity may be important in controlling the transition from reversible to irreversible heart hypertrophy. 48 In the present study, we demonstrate that hKv4.3 channel activity is decreased by both EGFR kinase and Src-family kinase inhibitors. This suggests that tyrosine phosphorylation of hKv4.3 channels may alter cardiac electrical activity, which is likely to play a compensatory role in which cardiac repolarization and excitability have been compromised.
In summary, the present study has provided evidence that hKv4.3 channel is positively regulated by EGFR kinase and Src-family kinases which phosphorylate Y136 residue and Y108 residue of the channel respectively, and the effect may be involved in the regulation of cellular electrical activity and thus may alter electrophysiological properties in human hearts.
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